At present, bamlanivimab and etesevimab — the other drug used in the treatment — are not authorized for use in the U.S. due to their diminished efficacy against the omicron variant.
“However, it is the recommendation of the U.S. government that product be retained in the event that future SARS-CoV-2 variants, which may be susceptible to bamlanivimab and etesevimab, emerge and become prevalent in the United States,” HHS said May 4.
Federal health officials are still reviewing whether to extend the shelf life for etesevimab and will provide an update on the matter in November, HHS said.
Learn more here.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
